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Problem Definition
Cardiovascular disease (CVD) remains the leading cause of
death in the United States, responsible for 840,768 deaths in
2016. From 2006 to 2016, the US death rate from
Cardiovascular disease decreased by 18.6% and decreased by
31.8% from coronary artery disease (CAD) specifically. This
decrease in mortality has largely been driven by early detection
and initiation of statin therapy. Atherosclerotic risk factors
have been evaluated in multiple longitudinal studies. These
studies have defined advancing age, male gender,
hypertension, dyslipidemias, diabetes, cigarette smoking and
family history as predictors of cardiac events. In addition to
this, an underrecognized surrogate marker for CAD is coronary
artery calcification (CAC). This should be considered
diagnostic for CAD. In the PROVIDI study, using a
qualitative scoring system for CAC, the authors found a
stepwise increase in the likelihood of cardiovascular events
with increasing CAC burden (four-fold increase in CV events in
patients with severe CAC relative to patients without CAC). Yet
despite this, CAC remains an under-recognized and underreported marker of CAD and an opportunity for improvement.

Fig 5. Percent of patients with CAC findings on CT who had an
internal PCP, followed-up with their PCP shortly after imaging and
had CAD discussed by PCP during that visit.
Fig 1. Distribution and severity of atherosclerotic findings on CT chest imaging.

Aims For Improvement
Overall aim: Improve diagnosis and management of CAD
based on CT chest imaging.
• Improve diagnosis of silent CAD based on CT chest imaging:
more patients who have findings of CAC on CT chest
imaging will be diagnosed with CAD.
• Increase the number of appropriate statin prescriptions
based on CAD findings on CT chest imaging.
Fig 2. Percent of patients with CAC on a statin based on severity .

Initial Measurement and Results

Intervention

Study population: For this project, we have selected a total
of 194 patients aged ≥40 years who had an inpatient stay at
TJUH between July of 2018 and June of 2019, did not have an
existing diagnosis of CAD and had CT imaging of the chest for
any indication.

Our proposed intervention has three components which will be
implemented sequentially.
1. Standardize the reporting format for CAC on CT chest
imaging by the Radiology Department.
Fig 3. Statin and aspirin prescriptions among the patients with CAC findings.

Results: There was a higher prevalence of females in this
study 57% compared to males 43%. The majority of the
patients fell into the age range of 60-79 and were White.
Among the patients with CAC on CT, 57% were not taking a
statin. Among the patients with diagnosis of diabetes and CAC
on CT, 33% were not taking a statin. 31% of patients with
hyperlipidemia and CAD findings were not taking a statin.
Among those who had severe CAC, 30% were not prescribed a
statin. Among them only 1 patient (2%) was prescribed
alternative cholesterol lowering medication (ezetimibe). Only
18% of patients who had CAC had CAD discussed in their chart.
31% of patients who had evidence of CAD on CT had follow-up
with cardiology. 48% of patients with CAC on CT had Jefferson
providers as PCP. Among them, 51% had follow-up with PCP
shortly after imaging and only 11% had CAD discussed during
that visit.

2. Creation of best practice advisory for CAC CT findings in
Epic. The goal is to alert the provider on the presence of
CAC, and thus CAD, and to consider statin initiation.
3. Educate Jefferson primary care providers on new best
practice advisory that will prompt them to have a
discussion about the presence of CAD and risks and
benefits of statin initiation.

Next Steps

Fig 4. Summary of important findings based on initial analysis of study population.

